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Objectives and methods of the ORCHESTRA 
FOUNDATION Registry study: a multicenter 
observational study of the use of insulin 
pump therapy in pregnant women with 
type 1 diabetes mellitus in Poland
ABSTRACT
Background. The ORCHESTRA FOUNDATION Registry 
study was a prospective, multicenter, observational, 
post-market study investigating the use of an insulin 
pump with or without continuous glucose monitor-
ing (CGM) [i.e., sensor-augmented pump (SAP) or 
sensor-integrated insulin pump (SIP)]; before, during, 
and after pregnancy, in women with type 1 diabetes 
mellitus (T1DM). 
Methods. Study participants enrolled in 24 centers, in 
Poland, and contributed intake and follow-up data for 
up to 22 months (i.e., up to 12 months pre-conception, 
throughout pregnancy, and 6 weeks after delivery). Par-
ticipants who were already pregnant were enrolled up 
to the 16th week of pregnancy. Investigated outcomes 
included HbA1c before and during pregnancy, and seri-
ous adverse events (e.g., severe hypoglycemia, diabetic 
ketoacidosis, miscarriage, and hospitalization due to 
any bleeding or any symptoms suggesting premature 
delivery). Routine clinical data including maternal 
weight, body mass index, and daily insulin use were 
also recorded. The insulin delivery devices used in 
the study were the MiniMed™ Paradigm™ REAL-Time 
insulin pump with CGM (via the MiniMed Sof-sensor™ 
sensor) or without CGM, and the MiniMed Paradigm 
Veo™ with CGM (via the Enlite™ sensor).
Results. Study enrollment began in May 2013 and the 
last patient completed the study in August 2017. 
Conclusions. The ORCHESTRA FOUNDATION Registry 
study provides an opportunity to assess the effects of 
automated insulin delivery in pregnant women with 
T1DM using insulin pumps with or without continuous 
glucose monitoring. (Clin Diabetol 2018; 7, 3: 136–144)
Key words: type 1 diabetes, continuous 
subcutaneous insulin infusion, pregnancy, registry 
study, sensor-augmented pump therapy; sensor- 
-integrated pump therapy
Introduction
Diabetes is the most common metabolic disease 
complicating pregnancy, and the number of pregnan-
cies complicated by diabetes is rising as the number 
of people with diabetes increases. Diabetes during 
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pregnancy is associated with considerable risks for both 
the mother and the fetus. Risks for the mother include 
miscarriage, hypoglycemia, ketoacidosis, preeclampsia, 
polyhydramnios, and premature or obstructed labor, 
which may necessitate caesarean section. Fetuses and 
neonates are at increased risk of congenital malforma-
tions, perinatal mortality, birth injuries, macrosomia, 
neonatal hypoglycemia, jaundice, and respiratory 
distress [1–8].
The relationship between glucose control before 
conception and the incidence of miscarriage and con-
genital malformations is well established [6, 9, 10]. 
High HbA1c levels in early pregnancy are associated 
with complications such as congenital malformations 
and miscarriage, while hyperglycemia in late pregnancy 
is associated with macrosomia leading to birth injury 
and caesarean section, other fetal morbidity [1, 1–5, 
8–11], and a potential predisposition to type 2 diabetes 
and obesity [12, 13].
Tight glucose control (HbA1c < 6.0%) during preg-
nancy is recommended by many guidelines [7, 14, 15], 
but achieving such control is challenging. It is crucial to 
achieve near-normal glycemic control before and during 
pregnancy, and to mimic the patterns of glucose levels 
seen in normal pregnancies. However, women with 
type 1 diabetes mellitus (T1DM) treated with multiple 
daily injections (MDI) throughout pregnancy experi-
ence prolonged daily exposure to higher than recom-
mended glucose levels, resulting in a 3–5-fold greater 
incidence of complications than that observed in the 
general population [11]. Some studies have shown 
that improvements in HbA1c levels achieved with MDI 
are associated with an increased risk of severe hypo-
glycemia, particularly nocturnal and undetected post-
prandial hyperglycemia [16–18]. Severe hypoglycemia 
affects 25–40% of pregnant women and is 3–5 times 
more common in early pregnancy than in the period 
before pregnancy [18, 19]. In one study, intensively 
treated pregnant women were 15 times more likely to 
experience severe hypoglycemia than women receiving 
conventional treatment [18]. During the first trimester 
of pregnancy, nocturnal hypoglycemia may be present 
in as many as 37% of pregnant women [20]. Although 
hypoglycemia is more harmful to the mother than to 
the fetus, hyperglycemia after episodes of hypoglyce-
mia and variable levels of glycemia may also be danger-
ous for the fetus [20–22].
In non-pregnant women with T1DM, continuous 
subcutaneous insulin infusion (CSII) has been shown 
to be associated with a reduced rate of severe hypogly-
cemia, compared with MDI therapy, without adversely 
affecting glycemic control [22]. Similarly, insulin pump 
use in pregnancy has been found to reduce HbA1c levels 
in patients with T1DM without increasing the rate of 
severe hypoglycemia or ketoacidosis [23]. Both CSII 
and continuous glucose monitoring (CGM), alone or 
in combination as a sensor-augmented pump (SAP) or 
sensor-integrated pump (SIP) therapy, improve glycemic 
control by reducing HbA1c from 0.4–1.2% [24–30]. The 
recent INTERPRET study, the largest and longest mul-
ticenter prospective study to date, has confirmed the 
effectiveness of CGM in pump users; data from 263 
patients using SAP therapy under real-life conditions 
over 12 months revealed significantly lower rates of 
hospitalization, greater treatment satisfaction, and 
reduced fear of hypoglycemia compared to CGM non-
users [31]. Other studies have also shown that the use of 
CGM and related features such as alarms and automatic 
insulin suspension (i.e., low glucose suspension [LGS]) 
reduces fear of hypoglycemia, the incidence of severe 
hypoglycemic events, and time spent in hypoglycemia 
[32–35]. More importantly, the use of the LGS feature 
does not result in rebound hyperglycemia [33].
While the frequency, magnitude, and duration of 
hyperglycemia or its link with prior hypoglycemia, are 
best captured by CGM, self-management of glycemia 
is essential for good glycemic control in diabetic pa-
tients. Postprandial glucose levels during pregnancy 
show a strong association with the incidence of mac-
rosomia [36]; and postprandial glucose monitoring 
and maintained glycemic targets have been shown to 
improve neonatal outcomes better than preprandial 
glucose monitoring [7]. Neonatal outcomes are more 
closely associated with hyperglycemic excursions, 
versus average daily glycemic control [37, 38]. Hence, 
the ability to analyze hypoglycemia and hyperglyce-
mia with CGM may be useful in detecting anticipated 
neonatal outcomes.
In summary, pump therapy, particularly that 
involving use of SAP or SIP systems, provides the 
technology to facilitate reduction of HbA1c before and 
during pregnancy. Such therapy can alert the mother 
to glucose excursions, and assist in preventing severe 
hypoglycemic events without incurring the risk of re-
bound hyperglycemia. For this reason, the Orchestra 
Foundation (Wielka Orkiestra Świątecznej Pomocy) 
funded the ORCHESTRA Registry study, to determine 
effectiveness of CSII therapy with and without CGM in 
pregnant women, in Poland. The design and methodo-
logy of this study are described in this paper.
Research design and methods
The study protocol was approved by Central Ethics 
Committee, and was valid for all participating centers. 
No Competent Authority approval was required for 
observational studies in Poland.
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Investigators and study duration
In total, 24 centers in Poland, identified by the 
Orchestra Foundation, participated in the study 
(See Supplemental Material). Enrollment began in 
May 2013, the last patient completed the study in 
August 2017, and data analysis has been completed 
in February 2018. 
Study design and objectives
The study was a national, prospective, multicenter, 
observational, post-market study of the effectiveness 
of commercially available devices [i.e., the MiniMed 
Paradigm REAL-Time insulin pump system (CSII with or 
without CGM); and the MiniMed Paradigm Veo insulin 
pump system with the Enlite™ sensor] (Medtronic, Po-
land). The primary objective was to assess the benefits 
of CSII and SAP on maternal glycemic control (HbA1c 
and CGM data). Secondary objectives were: 1) to as-
sess the prevalence of pregnancy complications (e.g., 
preterm delivery, low infant birth weight, neonatal care 
admissions) throughout pregnancy, during delivery, 
and during lactation for up to 6 weeks after delivery; 
2) to evaluate the potential benefits of CSII and SAP 
on neonatal outcomes; and 3) to evaluate changes in 
patient-reported outcomes, such as concerns about 
hypoglycemia and satisfaction with diabetes treatment.
Study population 
The study population consisted of women aged 
18–45 years with T1DM who either intended to become 
pregnant within 12 months or were already in the early 
stages of pregnancy (≤ 16 weeks). Women were eligible 
for inclusion in the study if they had been treated with 
MDI for, at least, 3 months and had indications for 
CSII, SAP or SIP. Women with type 2 diabetes, gesta-
tional diabetes or maturity-onset diabetes of the young 
(MODY) were excluded, as were patients using insulin 
pumps that had not been donated by the Orchestra 
Foundation. Women who required assisted fertilization 
technologies, or participated in any interventional clini-
cal trial within 3 months prior to screening, were also 
excluded. Written informed consent was obtained from 
all patients before enrollment in the study. 
Based on local data and experience, it was antici-
pated that in about two thirds of cases CSII would start 
during the first trimester of pregnancy (≤ 16 weeks). 
The estimated total sample size was 500 women, which 
included 100 with complete follow-up (from pre-
conception until 6 weeks post-delivery), 300 enrolled 
up to the 16th week of pregnancy, and 100 who may 
be expected to be withdrawn for various reasons. En-
rollment would stop when data from 100 participants 
with complete follow-up from pre-conception until 6 
weeks post-delivery had been collected. A flow chart 
summarizing enrollment and termination procedures 
is shown in Figure 1.
Pre-conception care 
There were 24 specialized centers in Poland with 
professional health care teams consisting of: a diabe-
tologist, diabetes educator, nurse, and dietitian. All 
women with T1DM participating in the pregnancy plan-
ning program received intensive diabetes management 
in these clinics. The intensive diabetes management 
involved education on diet and carbohydrate counting, 
physical activity, folic acid supplementation, glycemic 
goals, self-monitoring of blood glucose (SMBG), and 
self-adjusting insulin dose. Care included frequent 
Figure 1. Study enrollment and termination procedures
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outpatient visits, and hospitalization if necessary. All 
women were trained by a dietician and/or diabetes 
educator. The recommended standard caloric intake 
was 35 kcal/kg of body weight, of which 40–50% was 
to be covered by carbohydrates, 20–30% by fats, and 
30% by proteins. Excessive weight gain was addressed 
by reducing daily food intake accompanied by a regular 
daily self-assessment of urine ketones. According to the 
Polish Diabetes Association recommendations in year 
2015 [15], the therapeutic targets for all women plan-
ning a pregnancy or who are pregnant are: a) HbA1c 
< 6.1%, b) fasting SMBG within 60–90 mg/dl, and 
c) subsequent pre- and 1-hour postprandial SMBG 
within 60–120 mg/dl. The Association also recommends 
that all women planning a pregnancy receive a sup-
plementation of folic acid. The glycaemia monitoring 
plan was highly structured, in terms of both timing 
and frequency, and was provided to all women by the 
diabetes educator. Women were requested to wear 
a CGM system or to perform SMBG 8 to 10 times a day 
using a blood glucose meter transmitting to an insulin 
pump: fasting, before, and one hour after main meals, 
at bedtime, and between 2–4 am. 
Study procedures
Study visits and procedures are summarized in 
Table 1. All women had an initial pre-conception visit, 
with a second visit 12 ± 4 weeks after amenorrhea. 
Women who did not conceive within 12 months of the 
initial visit had a third visit at 12 months ± 2 weeks. 
Women who were already pregnant at enrollment had 
the initial visit at the time of enrollment. All pregnant 
women were assessed after 24 and 36 weeks (± 2 
weeks) of amenorrhea, at delivery, and 6 weeks after 
delivery (both ± 2 weeks). At each assessment, clini-
cal data were recorded in electronic case report forms 
(eCRFs), and data from devices (pumps and glucose me-
ters) were uploaded into CareLink™ Clinical software. 
Women who experienced a miscarriage kept their pump 
for an additional 3 months after the miscarriage, if they 
wished to continue insulin pump therapy. 
A CareLink USB was provided for uploading blood 
glucose meter or insulin pump data to CareLink Clinical 
software. In addition, a blood glucose meter compat-
ible with the CareLink Clinical software; insulin pump 
therapy consumables; and all necessary devices for 
insertion were provided. Except for the Enlite sensors, 
which are single-use devices, all devices were loaned 
to the study participants for the entire study period, 
after which they would be returned to the center in-
vestigators.
Approximately two thirds of the participants had 
been provided the Paradigm REAL-Time pump, and 
the remaining were provided the Paradigm Veo pump. 
The participants using the Paradigm REAL-Time system 
could use CGM (i.e., the MiniLink™ transmitter and 
Sof-Sensor sensor) at their own expense, if the HCP 
agreed to this. The participants using the Paradigm Veo 
received as many Enlite sensors free of charge as their 
health care professional (HCP) considered necessary. All 
participants received adequate training using a stand-
ardized training checklist on the use of insulin pumps, 
CGM, and consumables. This training was provided 
by the HCP at the investigation center, or a Certified 
Product Trainer, based on local practice. All participants 
were to have shown good compliance with, and an 
ability to understand and use, their therapy, as assessed 
by the treating physician.
Data recorded
Clinical outcomes
Maternal HbA1c levels before the initiation of 
insulin pump therapy were obtained retrospectively 
from medical records. HbA1c was measured on 2–3 
occasions during pregnancy, with a final measurement 
being made at the end of the study. Other clinical data 
collected included weight, BMI, daily insulin use, the 
number of SMBG measurements conducted per day 
(or self-reported by the participant), and the incidence 
of serious adverse events (e.g., severe hypoglycemia, 
diabetic ketoacidosis, miscarriage, hospitalizations). 
Concerns about hypoglycemia were assessed using 
the Hypoglycemia Fear Survey (HFS) at enrollment, on 
2–3 occasions during pregnancy, and 6 weeks after 
delivery. Satisfaction with diabetes treatment was as-
sessed by means of the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ) at the aforementioned occasions, 
and the DTSQc at pregnancy week 24 [39, 40]. Data on 
sensor and pump use during delivery, satisfaction with 
treatment during delivery, and additional participant-
reported outcomes were also recorded.
The following neonatal outcomes were recorded: 
incidence rates of mode of delivery (e.g., i.e., normal, 
elective, cesarean section (CS), and emergency CS), ges-
tational age at delivery, infant birth weight percentile 
[Large for Gestational Age (LGA), small for gestational 
age (SGA)], neonatal care admission, neonatal mor-
bidity, pregnancy-related serious adverse events, and 
feeding status on discharge from hospital. 
Adverse events 
Serious adverse events were defined as: a) events 
leading to death; b) events leading to life-threatening 
illness or injury, permanent anatomical or functional 
impairment, or in-patient or prolonged hospitalization 
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or medical or surgical intervention (particularly hypo-
glycemia or hyperglycemia); and c) events leading to 
fetal distress, fetal death or congenital abnormalities 
or birth defects. Potential device-related adverse events 
included: skin reactions to infusion set or sensor adhe-
sive, inflammation or bruising at the insulin infusion 
site, or incorrect insulin delivery. 
Statistical methods and analysis
All enrolled subjects who have participated in Or-
chestra Pregnancy Observational Study in Poland were 
included in the efficacy and safety analysis. Baseline 
information and demographic characteristics such as 
age, gender, weight, BMI, diabetes duration, insulin regi-
men, etc. were summarized. Medical information such 
as previous severe hypoglycemia and DKA history up to 
12 months prior to study start was also summarized.
Clinical and safety data were summarized using 
descriptive statistics for all available groups: 1) all en-
rolled; 2) those who failed to achieve a pregnancy; 3) 
those who become pregnant after the pre-conception 
phase; 4) those already pregnant at enrollment.
The primary analysis investigated the change in 
HbA1c from the beginning to the end of pregnancy. Sec-
ondary analyses included the following: the proportion 
of subjects achieving HbA1c < 6%, 6.5%, 7%, 7.5%, and 
8%; descriptive statistics for sensor glucose (e.g., mean, 
variability, percent in range and AUC) analyzed as overall 
and stratified by pregnancy outcome (no conception, 
delivery, miscarriage, etc.); and completeness of treat-
ment phase (i.e., complete follow-up, pregnancy and 6 
weeks after delivery, pre-conception phase only, etc.). 
Other maternal outcomes, such as weight, BMI, 
daily insulin requirements (units) at the moment of 
the visit, and microalbumin excretion with albumin/ 
/creatinine ratio were also collected.
Initial results after completed recrutation are 
shown in Figure 2.
Discussion
Insulin pump therapy has been shown to improve 
quality of life in pregnant women with diabetes [31, 
41]. The Orchestra Foundation facilitated use of insulin 
pumps by all pregnant women with type 1 diabetes in 
Poland; hence, all participants fulfilling study inclusion 
criteria were registered, and only those with contrain-
dications to insulin pump therapy were excluded from 
the study. The clinical study intended to recruit as many 
women as possible during the pre-conception period: 
approximately 20–30% participation was anticipated.
The advantage of this study design was the use 
of insulin delivery devices with the same platform by 
all participants. All studied women were Caucasian 
with T1DM. All study centers used the same devices 
and the same methods of education and training for 
participants. However, a limitation was that, although 
studies comparing the use of CSII and MDI have yielded 
inconsistent results [23, 29, 42–46], it was not possible 
to compare the results of pump use with a control 
group not using pump therapy and/or pump therapy 
supported by CGM. Nevertheless, this study offered a 
unique opportunity to follow a large patient population 
using standardized insulin-delivery devices to assess the 
prevalence of pregnancy complications and outcomes. 
It was also possible to compare the results of introduc-
ing pump therapy, with or without CGM, before and 
during pregnancy. 
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